New Zealand recorded 2282861 Coronavirus Cases since the epidemic began, according to the World Health Organization (WHO). In addition, New Zealand reported 2792 Coronavirus Deaths. This dataset includes a chart with historical data for New Zealand Coronavirus Cases.

In past 24 hours, New Zealand, Australia-Oceania had N/A new cases, N/A deaths and N/A recoveries.

Context

With the arrival of the COVID19 virus in New Zealand, the ministry of health is tracking new cases and releasing daily updates on the situation on their webpage: https://www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-current-cases and https://www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-current-cases/covid-19-current-cases-details. Much of the information given in these updates are not in a machine-friendly format. The objective of this dataset is to provide NZ Minstry of Health COVID19 data in easy-to-use format.

Content

All data in this dataset has been acquired from the New Zealand Minstry of Health's 'COVID19 current cases' webpage, located here: https://www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-current-cases. The Ministry of Health updates their page daily, that will be the targeted update frequency for this dataset for the Daily Count of Cases dataset. The Case Details dataset which includes travel details on each case will be updated weekly.

Limitations of this dataset

The mission of this project is to reliably convey data that the Ministry of Health has reported in the most digestable format. Enrichment of data is currently out of scope.

Help improve this dataset

If you find any discrepancies between the Ministry of Health's data and this dataset, please provide your feedback as an issue on the git repo for this dataset: https://github.com/2kruman/COVID19-NZ-known-cases/issues.

Summary statistics for the New Zealand epidemic by age and type of case.

As of November 16, 2020, 43 percent of COVID-19 infection cases in New Zealand were contracted through contact with a person who had recently travelled overseas. Less than five percent of cases were attributed to locally acquired cases where the infection source was unknown.

Based on a comparison of coronavirus deaths in 210 countries relative to their population, Peru had the most losses to COVID-19 up until July 13, 2022. As of the same date, the virus had infected over 557.8 million people worldwide, and the number of deaths had totaled more than 6.3 million. Note, however, that COVID-19 test rates can vary per country. Additionally, big differences show up between countries when combining the number of deaths against confirmed COVID-19 cases. The source seemingly does not differentiate between "the Wuhan strain" (2019-nCOV) of COVID-19, "the Kent mutation" (B.1.1.7) that appeared in the UK in late 2020, the 2021 Delta variant (B.1.617.2) from India or the Omicron variant (B.1.1.529) from South Africa.

The difficulties of death figures

This table aims to provide a complete picture on the topic, but it very much relies on data that has become more difficult to compare. As the coronavirus pandemic developed across the world, countries already used different methods to count fatalities, and they sometimes changed them during the course of the pandemic. On April 16, for example, the Chinese city of Wuhan added a 50 percent increase in their death figures to account for community deaths. These deaths occurred outside of hospitals and went unaccounted for so far. The state of New York did something similar two days before, revising their figures with 3,700 new deaths as they started to include “assumed” coronavirus victims. The United Kingdom started counting deaths in care homes and private households on April 29, adjusting their number with about 5,000 new deaths (which were corrected lowered again by the same amount on August 18). This makes an already difficult comparison even more difficult. Belgium, for example, counts suspected coronavirus deaths in their figures, whereas other countries have not done that (yet). This means two things. First, it could have a big impact on both current as well as future figures. On April 16 already, UK health experts stated that if their numbers were corrected for community deaths like in Wuhan, the UK number would change from 205 to “above 300”. This is exactly what happened two weeks later. Second, it is difficult to pinpoint exactly which countries already have “revised” numbers (like Belgium, Wuhan or New York) and which ones do not. One work-around could be to look at (freely accessible) timelines that track the reported daily increase of deaths in certain countries. Several of these are available on our platform, such as for Belgium, Italy and Sweden. A sudden large increase might be an indicator that the domestic sources changed their methodology.

Where are these numbers coming from?

The numbers shown here were collected by Johns Hopkins University, a source that manually checks the data with domestic health authorities. For the majority of countries, this is from national authorities. In some cases, like China, the United States, Canada or Australia, city reports or other various state authorities were consulted. In this statistic, these separately reported numbers were put together. For more information or other freely accessible content, please visit our dedicated Facts and Figures page.

This Project Tycho dataset includes a CSV file with COVID-19 data reported in NEW ZEALAND: 2019-12-30 - 2021-07-31. It contains counts of cases and deaths. Data for this Project Tycho dataset comes from: "COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University", "European Centre for Disease Prevention and Control Website", "World Health Organization COVID-19 Dashboard". The data have been pre-processed into the standard Project Tycho data format v1.1.

Near-term forecasting of infectious disease incidence and consequent demand for acute healthcare services can support capacity planning and public health responses. Despite well-developed scenario modelling to support the Covid-19 response, Aotearoa New Zealand lacks advanced infectious disease forecasting capacity. We develop a model using Aotearoa New Zealand’s unique Covid-19 data streams to predict reported Covid-19 cases, hospital admissions and hospital occupancy. The method combines a semi-mechanistic model for disease transmission to predict cases with Gaussian process regression models to predict the fraction of reported cases that will require hospital treatment. We evaluate forecast performance against out-of-sample data over the period from 2 October 2022 to 23 July 2023. Our results show that forecast performance is reasonably good over a 1-3 week time horizon, although generally deteriorates as the time horizon is lengthened. The model has been operationalised to provide weekly national and regional forecasts in real-time. This study is an important step towards development of more sophisticated situational awareness and infectious disease forecasting tools in Aotearoa New Zealand.

This 6MB download is a zip file containing 5 pdf documents and 2 xlsx spreadsheets. Presentation on COVID-19 and the potential impacts on employment

May 2020Waka Kotahi wants to better understand the potential implications of the COVID-19 downturn on the land transport system, particularly the potential impacts on regional economies and communities.

To do this, in May 2020 Waka Kotahi commissioned Martin Jenkins and Infometrics to consider the potential impacts of COVID-19 on New Zealand’s economy and demographics, as these are two key drivers of transport demand. In addition to providing a scan of national and international COVID-19 trends, the research involved modelling the economic impacts of three of the Treasury’s COVID-19 scenarios, to a regional scale, to help us understand where the impacts might be greatest.

Waka Kotahi studied this modelling by comparing the percentage difference in employment forecasts from the Treasury’s three COVID-19 scenarios compared to the business as usual scenario.

The source tables from the modelling (Tables 1-40), and the percentage difference in employment forecasts (Tables 41-43), are available as spreadsheets.

Arataki - potential impacts of COVID-19 Final Report

Employment modelling - interactive dashboard

The modelling produced employment forecasts for each region and district over three time periods – 2021, 2025 and 2031. In May 2020, the forecasts for 2021 carried greater certainty as they reflected the impacts of current events, such as border restrictions, reduction in international visitors and students etc. The 2025 and 2031 forecasts were less certain because of the potential for significant shifts in the socio-economic situation over the intervening years. While these later forecasts were useful in helping to understand the relative scale and duration of potential COVID-19 related impacts around the country, they needed to be treated with care recognising the higher levels of uncertainty.

The May 2020 research suggested that the ‘slow recovery scenario’ (Treasury’s scenario 5) was the most likely due to continuing high levels of uncertainty regarding global efforts to manage the pandemic (and the duration and scale of the resulting economic downturn).

The updates to Arataki V2 were framed around the ‘Slower Recovery Scenario’, as that scenario remained the most closely aligned with the unfolding impacts of COVID-19 in New Zealand and globally at that time.

Find out more about Arataki, our 10-year plan for the land transport system

May 2021The May 2021 update to employment modelling used to inform Arataki Version 2 is now available. Employment modelling dashboard - updated 2021Arataki used the May 2020 information to compare how various regions and industries might be impacted by COVID-19. Almost a year later, it is clear that New Zealand fared better than forecast in May 2020.Waka Kotahi therefore commissioned an update to the projections through a high-level review of:the original projections for 2020/21 against performancethe implications of the most recent global (eg International monetary fund world economic Outlook) and national economic forecasts (eg Treasury half year economic and fiscal update)The treasury updated its scenarios in its December half year fiscal and economic update (HYEFU) and these new scenarios have been used for the revised projections.Considerable uncertainty remains about the potential scale and duration of the COVID-19 downturn, for example with regards to the duration of border restrictions, update of immunisation programmes. The updated analysis provides us with additional information regarding which sectors and parts of the country are likely to be most impacted. We continue to monitor the situation and keep up to date with other cross-Government scenario development and COVID-19 related work. The updated modelling has produced employment forecasts for each region and district over three time periods - 2022, 2025, 2031.The 2022 forecasts carry greater certainty as they reflect the impacts of current events. The 2025 and 2031 forecasts are less certain because of the potential for significant shifts over that time.

Data reuse caveats: as per license.

Additionally, please read / use this data in conjunction with the Infometrics and Martin Jenkins reports, to understand the uncertainties and assumptions involved in modelling the potential impacts of COVID-19.

COVID-19’s effect on industry and regional economic outcomes for NZ Transport Agency [PDF 620 KB]

Data quality statement: while the modelling undertaken is high quality, it represents two point-in-time analyses undertaken during a period of considerable uncertainty. This uncertainty comes from several factors relating to the COVID-19 pandemic, including:

a lack of clarity about the size of the global downturn and how quickly the international economy might recover differing views about the ability of the New Zealand economy to bounce back from the significant job losses that are occurring and how much of a structural change in the economy is required the possibility of a further wave of COVID-19 cases within New Zealand that might require a return to Alert Levels 3 or 4.

While high levels of uncertainty remain around the scale of impacts from the pandemic, particularly in coming years, the modelling is useful in indicating the direction of travel and the relative scale of impacts in different parts of the country.

Data quality caveats: as noted above, there is considerable uncertainty about the potential scale and duration of the COVID-19 downturn. Please treat the specific results of the modelling carefully, particularly in the forecasts to later years (2025, 2031), given the potential for significant shifts in New Zealand's socio-economic situation before then.

As such, please use the modelling results as a guide to the potential scale of the impacts of the downturn in different locations, rather than as a precise assessment of impacts over the coming decade.

On March 10, 2023, the Johns Hopkins Coronavirus Resource Center ceased its collecting and reporting of global COVID-19 data. For updated cases, deaths, and vaccine data please visit the following sources: World Health Organization (WHO)For more information, visit the Johns Hopkins Coronavirus Resource Center.-- Esri COVID-19 Trend Report for 3-9-2023 --0 Countries have Emergent trend with more than 10 days of cases: (name : # of active cases) 41 Countries have Spreading trend with over 21 days in new cases curve tail: (name : # of active cases)Monaco : 13, Andorra : 25, Marshall Islands : 52, Kyrgyzstan : 79, Cuba : 82, Saint Lucia : 127, Cote d'Ivoire : 148, Albania : 155, Bosnia and Herzegovina : 172, Iceland : 196, Mali : 198, Suriname : 246, Botswana : 247, Barbados : 274, Dominican Republic : 304, Malta : 306, Venezuela : 334, Micronesia : 346, Uzbekistan : 356, Afghanistan : 371, Jamaica : 390, Latvia : 402, Mozambique : 406, Kosovo : 412, Azerbaijan : 427, Tunisia : 528, Armenia : 594, Kuwait : 716, Thailand : 746, Norway : 768, Croatia : 847, Honduras : 1002, Zimbabwe : 1067, Saudi Arabia : 1098, Bulgaria : 1148, Zambia : 1166, Panama : 1300, Uruguay : 1483, Kazakhstan : 1671, Paraguay : 2080, Ecuador : 53320 Countries may have Spreading trend with under 21 days in new cases curve tail: (name : # of active cases)61 Countries have Epidemic trend with over 21 days in new cases curve tail: (name : # of active cases)Liechtenstein : 48, San Marino : 111, Mauritius : 742, Estonia : 761, Trinidad and Tobago : 1296, Montenegro : 1486, Luxembourg : 1540, Qatar : 1541, Philippines : 1915, Ireland : 1946, Brunei : 2010, United Arab Emirates : 2013, Denmark : 2111, Sweden : 2149, Finland : 2154, Hungary : 2169, Lebanon : 2208, Bolivia : 2838, Colombia : 3250, Switzerland : 3321, Peru : 3328, Slovakia : 3556, Malaysia : 3608, Indonesia : 3793, Portugal : 4049, Cyprus : 4279, Argentina : 5050, Iran : 5135, Lithuania : 5323, Guatemala : 5516, Slovenia : 5689, South Africa : 6604, Georgia : 7938, Moldova : 8082, Israel : 8746, Bahrain : 8932, Netherlands : 9710, Romania : 12375, Costa Rica : 12625, Singapore : 13816, Serbia : 14093, Czechia : 14897, Spain : 17399, Ukraine : 19568, Canada : 24913, New Zealand : 25136, Belgium : 30599, Poland : 38894, Chile : 41055, Australia : 50192, Mexico : 65453, United Kingdom : 65697, France : 68318, Italy : 70391, Austria : 90483, Brazil : 134279, Korea - South : 209145, Russia : 214935, Germany : 257248, Japan : 361884, US : 6440500 Countries may have Epidemic trend with under 21 days in new cases curve tail: (name : # of active cases) 54 Countries have Controlled trend: (name : # of active cases)Palau : 3, Saint Kitts and Nevis : 4, Guinea-Bissau : 7, Cabo Verde : 8, Mongolia : 8, Benin : 9, Maldives : 10, Comoros : 10, Gambia : 12, Bhutan : 14, Cambodia : 14, Syria : 14, Seychelles : 15, Senegal : 16, Libya : 16, Laos : 17, Sri Lanka : 19, Congo (Brazzaville) : 19, Tonga : 21, Liberia : 24, Chad : 25, Fiji : 26, Nepal : 27, Togo : 30, Nicaragua : 32, Madagascar : 37, Sudan : 38, Papua New Guinea : 38, Belize : 59, Egypt : 60, Algeria : 64, Burma : 65, Ghana : 72, Haiti : 74, Eswatini : 75, Guyana : 79, Rwanda : 83, Uganda : 88, Kenya : 92, Burundi : 94, Angola : 98, Congo (Kinshasa) : 125, Morocco : 125, Bangladesh : 127, Tanzania : 128, Nigeria : 135, Malawi : 148, Ethiopia : 248, Vietnam : 269, Namibia : 422, Cameroon : 462, Pakistan : 660, India : 4290 41 Countries have End Stage trend: (name : # of active cases)Sao Tome and Principe : 1, Saint Vincent and the Grenadines : 2, Somalia : 2, Timor-Leste : 2, Kiribati : 8, Mauritania : 12, Oman : 14, Equatorial Guinea : 20, Guinea : 28, Burkina Faso : 32, North Macedonia : 351, Nauru : 479, Samoa : 554, China : 2897, Taiwan* : 249634 -- SPIKING OF NEW CASE COUNTS --20 countries are currently experiencing spikes in new confirmed cases:Armenia, Barbados, Belgium, Brunei, Chile, Costa Rica, Georgia, India, Indonesia, Ireland, Israel, Kuwait, Luxembourg, Malaysia, Mauritius, Portugal, Sweden, Ukraine, United Kingdom, Uzbekistan 20 countries experienced a spike in new confirmed cases 3 to 5 days ago: Argentina, Bulgaria, Croatia, Czechia, Denmark, Estonia, France, Korea - South, Lithuania, Mozambique, New Zealand, Panama, Poland, Qatar, Romania, Slovakia, Slovenia, Switzerland, Trinidad and Tobago, United Arab Emirates 47 countries experienced a spike in new confirmed cases 5 to 14 days ago: Australia, Austria, Bahrain, Bolivia, Brazil, Canada, Colombia, Congo (Kinshasa), Cyprus, Dominican Republic, Ecuador, Finland, Germany, Guatemala, Honduras, Hungary, Iran, Italy, Jamaica, Japan, Kazakhstan, Lebanon, Malta, Mexico, Micronesia, Moldova, Montenegro, Netherlands, Nigeria, Pakistan, Paraguay, Peru, Philippines, Russia, Saint Lucia, Saudi Arabia, Serbia, Singapore, South Africa, Spain, Suriname, Thailand, Tunisia, US, Uruguay, Zambia, Zimbabwe 194 countries experienced a spike in new confirmed cases over 14 days ago: Afghanistan, Albania, Algeria, Andorra, Angola, Antigua and Barbuda, Argentina, Armenia, Australia, Austria, Azerbaijan, Bahamas, Bahrain, Bangladesh, Barbados, Belarus, Belgium, Belize, Benin, Bhutan, Bolivia, Bosnia and Herzegovina, Botswana, Brazil, Brunei, Bulgaria, Burkina Faso, Burma, Burundi, Cabo Verde, Cambodia, Cameroon, Canada, Central African Republic, Chad, Chile, China, Colombia, Comoros, Congo (Brazzaville), Congo (Kinshasa), Costa Rica, Cote d'Ivoire, Croatia, Cuba, Cyprus, Czechia, Denmark, Djibouti, Dominica, Dominican Republic, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Estonia, Eswatini, Ethiopia, Fiji, Finland, France, Gabon, Gambia, Georgia, Germany, Ghana, Greece, Grenada, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Honduras, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kiribati, Korea - South, Kosovo, Kuwait, Kyrgyzstan, Laos, Latvia, Lebanon, Lesotho, Liberia, Libya, Liechtenstein, Lithuania, Luxembourg, Madagascar, Malawi, Malaysia, Maldives, Mali, Malta, Marshall Islands, Mauritania, Mauritius, Mexico, Micronesia, Moldova, Monaco, Mongolia, Montenegro, Morocco, Mozambique, Namibia, Nauru, Nepal, Netherlands, New Zealand, Nicaragua, Niger, Nigeria, North Macedonia, Norway, Oman, Pakistan, Palau, Panama, Papua New Guinea, Paraguay, Peru, Philippines, Poland, Portugal, Qatar, Romania, Russia, Rwanda, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Samoa, San Marino, Sao Tome and Principe, Saudi Arabia, Senegal, Serbia, Seychelles, Sierra Leone, Singapore, Slovakia, Slovenia, Solomon Islands, Somalia, South Africa, South Sudan, Spain, Sri Lanka, Sudan, Suriname, Sweden, Switzerland, Syria, Taiwan*, Tajikistan, Tanzania, Thailand, Timor-Leste, Togo, Tonga, Trinidad and Tobago, Tunisia, Turkey, Tuvalu, US, Uganda, Ukraine, United Arab Emirates, United Kingdom, Uruguay, Uzbekistan, Vanuatu, Venezuela, Vietnam, West Bank and Gaza, Yemen, Zambia, Zimbabwe Strongest spike in past two days was in US at 64,861 new cases.Strongest spike in past five days was in US at 64,861 new cases.Strongest spike in outbreak was 424 days ago in US at 1,354,505 new cases. Global Total Confirmed COVID-19 Case Rate of 8620.91 per 100,000Global Active Confirmed COVID-19 Case Rate of 37.24 per 100,000Global COVID-19 Mortality Rate of 87.69 per 100,000 21 countries with over 200 per 100,000 active cases.5 countries with over 500 per 100,000 active cases.3 countries with over 1,000 per 100,000 active cases.1 country with over 2,000 per 100,000 active cases.Nauru is worst at 4,354.54 per 100,000.

Learning outcomes:Students will gain an understanding of the global patterns of COVID-19 cases, and how this information changes over time.Students will also compare the COVID-19 data with the World Health Organisations health statistics.Other New Zealand GeoInquiry instructional material freely available at https://arcg.is/1GPDXe

Context

This dataset was collected from data received via this APi.

Content

“[Recovered cases are a] more important metric to track than Confirmed cases.”— Researchers for the University of Virginia’s COVID-19 dashboard

If the number of total cases were accurately known for every country then the number of cases per million people would be a good indicator as to how well various countries are handling the pandemic.

Countries:

Datasets contend data about covid_19 from 232 countries - Afghanistan - Albania - Algeria - Andorra - Angola - Anguilla - Antigua-and-Barbuda - Argentina - Armenia - Aruba - Australia - Austria - Azerbaijan - Bahamas - Bahrain - Bangladesh - Barbados - Belarus - Belgium - Belize - Benin - Bermuda - Bhutan - Bolivia - Bosnia-and-Herzegovina - Botswana - Brazil - British-Virgin-Islands - Brunei - Bulgaria - Burkina-Faso - Burundi - Cabo-Verde - Cambodia - Cameroon - Canada - CAR - Caribbean-Netherlands - Cayman-Islands - Chad - Channel-Islands - Chile - China - Colombia - Comoros - Congo - Cook-Islands - Costa-Rica - Croatia - Cuba - Curaçao - Cyprus - Czechia - Denmark - Diamond-Princess - Diamond-Princess- - Djibouti - Dominica - Dominican-Republic - DRC - Ecuador - Egypt - El-Salvador - Equatorial-Guinea - Eritrea - Estonia - Eswatini - Ethiopia - Faeroe-Islands - Falkland-Islands - Fiji - Finland - France - French-Guiana - French-Polynesia - Gabon - Gambia - Georgia - Germany - Ghana - Gibraltar - Greece - Greenland - Grenada - Guadeloupe - Guam - Guatemala - Guinea - Guinea-Bissau - Guyana - Haiti - Honduras - Hong-Kong - Hungary - Iceland - India - Indonesia - Iran - Iraq - Ireland - Isle-of-Man - Israel - Italy - Ivory-Coast - Jamaica - Japan - Jordan - Kazakhstan - Kenya - Kiribati - Kuwait - Kyrgyzstan - Laos - Latvia - Lebanon - Lesotho - Liberia - Libya - Liechtenstein - Lithuania - Luxembourg - Macao - Madagascar - Malawi - Malaysia - Maldives - Mali - Malta - Marshall-Islands - Martinique - Mauritania - Mauritius - Mayotte - Mexico - Micronesia - Moldova - Monaco - Mongolia - Montenegro - Montserrat - Morocco - Mozambique - MS-Zaandam - MS-Zaandam- - Myanmar - Namibia - Nepal - Netherlands - New-Caledonia - New-Zealand - Nicaragua - Niger - Nigeria - Niue - North-Macedonia - Norway - Oman - Pakistan - Palau - Palestine - Panama - Papua-New-Guinea - Paraguay - Peru - Philippines - Poland - Portugal - Puerto-Rico - Qatar - Réunion - Romania - Russia - Rwanda - S-Korea - Saint-Helena - Saint-Kitts-and-Nevis - Saint-Lucia - Saint-Martin - Saint-Pierre-Miquelon - Samoa - San-Marino - Sao-Tome-and-Principe - Saudi-Arabia - Senegal - Serbia - Seychelles - Sierra-Leone - Singapore - Sint-Maarten - Slovakia - Slovenia - Solomon-Islands - Somalia - South-Africa - South-Sudan - Spain - Sri-Lanka - St-Barth - St-Vincent-Grenadines - Sudan - Suriname - Sweden - Switzerland - Syria - Taiwan - Tajikistan - Tanzania - Thailand - Timor-Leste - Togo - Tonga - Trinidad-and-Tobago - Tunisia - Turkey - Turks-and-Caicos - UAE - Uganda - UK - Ukraine - Uruguay - US-Virgin-Islands - USA - Uzbekistan - Vanuatu - Vatican-City - Venezuela - Vietnam - Wallis-and-Futuna - Western-Sahara - Yemen - Zambia - Zimbabw-

The purpose of this project is to write a large and in sync dataset focused patient characteristics for identify the Risk groups and characteristics human-level that impact on infection, Complication and Death as a result of the disease

for more detail about the data:

https://docs.google.com/spreadsheets/d/1awEY-04UK8wibkbZ1qfV6a-Q9YKScfP7qiAtWDsp9Jw/edit?usp=sharing

last date for update 06.12.2020

4535323 rows

Version 5:

A version that includes cleaning the data and engineering new features for more detail : https://docs.google.com/spreadsheets/d/1awEY-04UK8wibkbZ1qfV6a-Q9YKScfP7qiAtWDsp9Jw/edit?usp=sharing

Version 6:

Machine-ready version of machine learning model Consists only of INT and FLOAT for more detail : https://docs.google.com/spreadsheets/d/1awEY-04UK8wibkbZ1qfV6a-Q9YKScfP7qiAtWDsp9Jw/edit?usp=sharing

problem with dataset

• There may be duplicate cases (which come from different data systems) Focusing on countries: France, Korea, Indonesia, Tunisia, Japan, canada, new_zealand, singapore, guatemala, philippines, india, vietnam, hong kong , Toronto, Mexico.

• I did not check the credibility of the sources

• Concerns of the credibility of the Mexican government's data

• Concerns about the credibility of the data of the Chinese government

Acknowledgements and Sources

india_wiki https://www.kaggle.com/karthikcs1/covid19-coronavirus-patient-list-karnataka-india

philippines https://www.kaggle.com/sundiver/covid19-philippines-edges

france https://www.kaggle.com/lperez/coronavirus-france-dataset

korea https://www.kaggle.com/kimjihoo/coronavirusdataset

indonesia https://www.kaggle.com/ardisragen/indonesia-coronavirus-cases

tunisia https://www.kaggle.com/ghassen1302/coronavirus-tunisia

japan https://www.kaggle.com/tsubasatwi/close-contact-status-of-corona-in-japan

world https://github.com/beoutbreakprepared/nCoV2019/tree/master/latest_data

canada https://www.kaggle.com/ryanxjhan/coronaviruscovid19-canada

new_zealand https://www.kaggle.com/madhavkru/covid19-nz

singapore https://www.kaggle.com/rhodiumbeng/singapores-covid19-cases

guatemala https://www.kaggle.com/ncovgt2020/covid19-guatemala

colombia https://www.kaggle.com/sebaxtian/covid19co

mexico https://www.kaggle.com/lalish99/covid19-mx

india_data https://www.kaggle.com/samacker77k/covid19india

vietnam https://www.kaggle.com/nh

kerla https://www.kaggle.com/baburajr/covid19inkerala

hong_kong https://www.kaggle.com/teddyteddywu/covid-19-hong-kong-cases

toronto https://www.kaggle.com/divyansh22/toronto-covid19-cases

Determining the severity illness according to WHO: https://www.who.int/publications/i/item/clinical-management-of-covid-19

• Each update contains the information found in the previous version

*Thanks to all sources

*If you have any helpful information or suggestions for improvement, write

Building notebook

• netbook PART A - cleaning and conact the data: https://www.kaggle.com/shirmani/characteristics-of-corona-patient-ds-v4

• netbook PART B- features Engineering: https://www.kaggle.com/shirmani/build-characteristics-corona-patients-part-b/edit

• part C data QA https://www.kaggle.com/shirmani/qa-characteristics-corona-patients-part-c

• netbook PART D - format the data to int and float cols (model preparation): https://www.kaggle.com/shirmani/build-characteristics-corona-patients-part-d

As of January 23, 2021, Vermont had the highest Rt value of any U.S. state. The Rt value indicates the average number of people that one person with COVID-19 is expected to infect. A number higher than one means each infected person is passing the virus to more than one other person.

Which are the hardest-hit states? The U.S. reported its first confirmed coronavirus case toward the end of January 2020. More than 28 million positive cases have since been recorded as of February 24, 2021 – California and Texas are the states with the highest number of coronavirus cases in the United States. When figures are adjusted to reflect each state’s population, North Dakota has the highest rate of coronavirus cases. The vaccine rollout has provided Americans with a significant morale boost, and California is the state with the highest number of COVID-19 vaccine doses administered.

How have other nations responded? Countries around the world have responded to the pandemic in varied ways. The United Kingdom has approved three vaccines for emergency use and ranks among the countries with the highest number of COVID-19 vaccine doses administered worldwide. In the Asia-Pacific region, the outbreak has been brought under control in New Zealand, and the country’s response to the pandemic has been widely praised.

Data-set of the paper Disentangling Covid-19, Economic Mobility, and Containment Policy Shocks for replication purpose of the Data Editor of AEJMacro. Detailed information on the data-set is in the readme file in the public repository openicpsr-175241 (under review).

We study the dynamic interaction between Covid-19, economic mobility, and containment policy. We use Bayesian panel structural vector autoregressions with daily data for 44 countries, identified through traditional and narrative sign restrictions. We find that incidence shocks and containment shocks have large and persistent effects on mobility, morbidity, and mortality that last for 1-2 months. These shocks are the main drivers of the pandemic, explaining between 20-60% of the average and historical variability in mobility, cases, and deaths worldwide. The policy tradeoff associated to non-pharmaceutical interventions is 1pp less economic mobility per day for 8% fewer deaths after three months.

The panel data-set contains the main data to perform the analysis in the paper. It contains dailiy data for (in sheets) Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Indonesia, Ireland, Israel, Italy, Japan, Lithuania, Luxembourg, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Russia, Saudi Arabia, Slovenia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Arab Emirates, United Kingdom and United States. Included variables are: Confirmed Cases, Total Deaths, Days Last Reported Case, Total Tests, School Closing, Workplace Closing, Cancel Public Events, Restrictions Gatherings, Close Public Transport, Stay at Home Requirements, Restrictions Internal Movement, International Travel Controls, Income Support, Debt/Contract Relief, Fiscal Measures, International Support, Public Information Campaigns, Testing Policy, Contact Tracing, Healthcare Emergency Investment, Investment Vaccines, Stringency Index, Small Cap, Large Cap, Government Benchmarks 3 Month, Government Benchmarks 1 Year, Government Benchmarks 2 Year, Government Benchmarks 5 Year, Government Benchmarks 10 Year, FX Indices Broad, FX Indices Narrow, Mobility Retail Mobility Grocery, Mobility Parks, Mobility Transit Stations Mobility Workplaces, Mobility Residential. Period: 30.12.2016 to 31.08.2020. All data are downloaded from Macrobond.

Vaccination is indeed one of the interventional strategies available to combat coronavirus disease (COVID-19). This study emphasizes the relevance of citizens' acceptance of the COVID-19 vaccine in assisting global recovery from the pandemic and aiding the tourism industries to return to normalcy. This study further presented the impact of COVID-19 on the tourism industry in China. Also, the study confirmed the past performance of tourism in China to the current tourism-related COVID-19 effects from a global perspective by employing Australia's outbound tourism data from 2008 to 2020 on top 6 destinations, including China, Indonesia, New Zealand, Thailand, the United Kingdom, and the United States.

To report bilateral relentless placoid chorioretinitis following Pfizer–BioNTech coronavirus disease 2019 (COVID-19) vaccine administration. A 55-year-old Caucasian New Zealand-born woman presented with progressive left eye vision loss and bilateral photopsias and floaters occurring 10 days after receiving the Pfizer–BioNTech COVID-19 vaccination. She had a similar self-limiting episode of photopsias and floaters without vision loss 1 year prior after receiving the influenza vaccine. Snellen visual acuity (VA) was 20/25 in the right eye, and count fingers at 2 m in the left eye. Bilateral, active, creamy, plaque-like lesions were present at the level of the retinal pigment epithelium and choroid, suggestive of relentless placoid chorioretinitis. Commencement of 100 mg oral prednisolone and 3 g mycophenolate daily resulted in recovery of the foveal ellipsoid layer with VA of 20/25 in each eye after 8 weeks. Subsequent activations occurred following COVID-19 infection and respiratory infection. This is the first reported case of relentless placoid chorioretinitis occurring as a potential side-effect of the Pfizer–BioNTech COVID-19 vaccine. Vaccination, and not infection, could be assumed to be the likely trigger. Subsequent flares following COVID-19 and a nonspecific respiratory infection during periods of inadequate immunosuppression suggest that a COVID-19 antigen or general immune activation could also be the trigger.

During the COVID-19 pandemic there have been marked changes in individuals' belief systems (e.g., support for lockdowns) as a result of the threat of COVID-19. In the current study, we investigated whether these belief systems change as a function of changes in the threat of COVID-19. Specifically, we conducted a longitudinal study, with authoritarianism measured at the height of the COVID-19 pandemic in New Zealand and when the threat of COVID-19 was low (i.e., no known COVID-19 cases in the community). A total of 888 participants responded at both timepoints, completing measures of political orientation and distrust of science, in addition to the measure of authoritarianism. We had two hypotheses. First, that liberals would display a more marked reduction in authoritarian submission between Alert Level 4 and Alert Level 1 relative to conservatives. Second, that changes would be mediated by trust in science. Both hypotheses were supported, demonstrating that authoritarianism is sensitive to threat, even for those on the political left, and that trust in science helps to explain these changes. We suggest that fluctuations in authoritarianism may be different across the political spectrum due to underlying belief systems such as a distrust of science.

The continuous evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants poses a challenge to determine the optimal updated composition of the coronavirus disease 2019 (COVID-19) vaccine. The present study aimed to investigate the immunogenicity of the Delta monovalent vaccine, the Omicron monovalent vaccine, and the Delta and Omicron BA.1 bivalent vaccine. Three COVID-19 vaccines were designed using the heterologous DNA prime-protein boost strategy, with each vaccine containing either Delta receptor-binding domain (RBD) of the spike protein, Omicron RBD, or both Delta and Omicron antigens. Temporal serum antibody binding titers and neutralizing antibody titers induced by the three vaccines in New Zealand White rabbits were analyzed. To further dissect the vaccine elicited antibodies (mAb) responses at the molecular level, a panel of rabbit monoclonal antibodies (RmAbs) was generated by a high-throughput single B cell sorting and discovery pipeline and further comprehensively characterized. The Omicron monovalent vaccine induced higher antibody binding titers and neutralization activities than the Delta and Omicron bivalent vaccine. Four RmAbs with robust neutralization capacity were isolated from rabbits immunized with the Omicron or Delta monovalent vaccine. Notably, 9E11 isolated from the Omicron monovalent vaccine group neutralized all the Omicron subvariants with an IC50 value ranging from 1.5 to 503.6 ng/mL; thus, this vaccine could serve as a prophylactic and therapeutic intervention. Given the increasing incidence of COVID-19 cases due to the Omicron variant, RBD from the Omicron strain could serve as a candidate immunogen that can induce higher neutralization activities against the SARS-CoV-2 Omicron sublineages.

The aims of this study were to examine the effectiveness of a range of smartphone apps for managing symptoms of anxiety and depression and to assess the utility of a single-case research design for enhancing the evidence base for this mode of treatment delivery. The study was serendipitously impacted by the COVID-19 pandemic, which allowed for effectiveness to be additionally observed in the context of significant community distress. A pilot study was initially conducted using theSuperBetter app to evaluate the proposed methodology, which proved successful with the four finishing participants. In the main study, 39 participants commenced (27 females and 12 males,MAge = 34.04 years,SD = 12.20), with 29 finishing the intervention phase and completing post-intervention measures. At 6-month follow-up, a further three participants could not be contacted. This study used a digitally enhanced, multiple baseline across-individuals single-case research design. Participants were randomly assigned to the following apps:SuperBetter (n = 8),Smiling Mind (n = 7),MoodMission (n = 8),MindShift (n = 8), andDestressify (n = 8). Symptomatology and life functioning were measured at five different time points: pre-baseline/screening, baseline, intervention, 3-week post-intervention, and 6-month follow-up. Detailed individual perceptions and subjective ratings of the apps were also obtained from participants following the study’s completion. Data were analyzed using visual inspection, time-series analysis, and methods of statistical and clinical significance. Positive results were observed for all apps. Overall, more favorable outcomes were achieved by younger participants, those concurrently undertaking psychotherapy and/or psychotropic medication, those with anxiety and mixed anxiety and depression rather than stand-alone depression, and those with a shorter history of mental illness. Outcomes were generally maintained at 6-month follow-up. It was concluded that a diverse range of evidence-based therapies offered via apps can be effective in managing mental health and improving life functioning even during times of significant global unrest and, like all psychotherapies, are influenced by client features. Additionally, this single-case research design is a low-cost/high value means of assessing the effectiveness of mental health apps.Clinical Trial Registration: The study is registered with the Australian and New Zealand Clinical Trials Registry (ANZCTR), which is a primary registry in the World Health Organization Registry Network, registration number ACTRN12619001302145p (http://www.ANZCTR.org.au/ACTRN12619001302145p.aspx).